DOCSLIB.ORG

Targeting ETS Gene Fusions in Cancer

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Targeting ETS Gene Fusions in Cancer Published OnlineFirst June 23, 2014; DOI: 10.1158/1078-0432.CCR-13-0275 Clinical Cancer Molecular Pathways Research Molecular Pathways: Targeting ETS Gene Fusions in Cancer Felix Y. Feng1,2,3, J. Chad Brenner2,3,4,5, Maha Hussain3,6,7, and Arul M. Chinnaiyan2,3,4,7,8 Abstract Rearrangements, or gene fusions, involving the ETS family of transcription factors are common driving events in both prostate cancer and Ewing sarcoma. These rearrangements result in pathogenic expression of the ETS genes and trigger activation of transcriptional programs enriched for invasion and other oncogenic features. Although ETS gene fusions represent intriguing therapeutic targets, transcription factors, such as those comprising the ETS family, have been notoriously difficult to target. Recently, preclinical studies have demonstrated an association between ETS gene fusions and components of the DNA damage response pathway, such as PARP1, the catalytic subunit of DNA protein kinase (DNAPK), and histone deactylase 1 (HDAC1), and have suggested that ETS fusions may confer sensitivity to inhibitors of these DNA repair proteins. In this review, we discuss the role of ETS fusions in cancer, the preclinical rationale for targeting ETS fusions with inhibitors of PARP1, DNAPK, and HDAC1, as well as ongoing clinical trials targeting ETS gene fusions. Clin Cancer Res; 20(17); 4442–8. Ó2014 AACR. Background tion domain (from the EWS gene) to the ETS fusion and ETS transcription factors are aberrantly expressed in (ii) replacement of the N-terminus of the ETS protein by several cancers, including prostate cancer (1), the Ewing an RNA-binding domain from the EWS protein that sarcoma family of tumors (2), melanoma (3), secretory enhances posttranscriptional splicing of ETS target genes breast carcinoma (4), acute lymphoblastic leukemia (5), (10; Fig. 1). gastrointestinal stromal tumors (6), and rare cases of Both prostate cancer and Ewing sarcoma ETS genomic acute myelogenous leukemia (7). The ETS family consists rearrangements are thought to occur early in malignant TMPRSS2–ERG of 28 unique genes (reviewed in ref. 8), of which ERG, progression. For example, fusions are FLI1,andETV1 are the most frequently deregulated in observed during the transition from high-grade prostatic cancer. Prostate cancer frequently harbors rearrange- intraepithelial neoplasia lesions to invasive carcinoma ments of ETS genes, in which ERG (50% of all prostate (9, 11) and are formed at high frequency in androgen- cancers) and ETV1 (5%) are fused to the androgen-reg- stimulated cell lines under genotoxic stress (12–14). ulated promoter and 50 untranslated region of the However, mice genetically engineered to express andro- ERG ETV1 TMPRSS2 gene (1, 9). This creates an androgen-regulated gen-regulated or develop prostatic intraepithelial TMPRSS2–ETS fusion transcript that encodes a nearly neoplasia-like lesions, but do not progress to frank full-length ETS transcription factor (Fig. 1). In addition, carcinoma (9, 11, 15–17). This suggests that complete almost all Ewing sarcomas contain an ETS rearrangement, ETS-mediated transformation may require additional col- including EWS–FLI1 (90%) or EWS–ERG (5%–10%) laborating mutations. While this spectrum is only begin- gene fusions, which encode a chimeric protein notable ning to emerge (18–20), it is clear that ERG accelerates for several features, including (i) provision of an activa- prostate carcinogenesis following loss of a highly recurrent prostate cancer tumor suppressor protein called PTEN or in the context of overexpression of the androgen receptor 1Department of Radiation Oncology, University of Michigan Medical (15–17). Interestingly, TMPRSS2–ERG overexpression School, Ann Arbor, Michigan. 2Michigan Center for Translational Pathol- leads to increased self-renewal over multiple plating gen- 3 ogy, University of Michigan Medical School, Ann Arbor, Michigan. Com- hi þ prehensive Cancer Center, University of Michigan Medical School, Ann erations in Sca-1 /EpCAM basal/progenitor cells isolated Arbor, Michigan. 4Department of Pathology, University of Michigan Medical from genetically engineered mice (21), suggesting a role for School, Ann Arbor, Michigan. 5Department of Otolaryngology, University of ETS fusions in prostate cancer progenitor populations. In Michigan Medical School, Ann Arbor, Michigan. 6Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan Med- contrast with prostate cancer, the cells from which Ewing ical School, Ann Arbor, Michigan. 7Department of Urology, University of sarcomas are derived are still unknown, limiting the inter- 8 Michigan Medical School, Ann Arbor, Michigan. Howard Hughes Medical pretation of genetic mouse models. Despite this impedi- Institute, University of Michigan Medical School, Ann Arbor, Michigan. ment, EWS–FLI1 overexpression has been shown to induce Corresponding Author: Arul M. Chinnaiyan, University of Michigan Med- ical School, 1400 E. Medical Center Drive, 5316 CCGC 5940, Ann Arbor, MI leukemic phenotypes when expressed in hematopoietic 48109-5940. Phone: 734-615-4062; Fax: 734-615-4055; E-mail: stem cells (22), to induce skeletal disruption when [email protected] expressed in mesenchymal progenitors using a PRX1 pro- doi: 10.1158/1078-0432.CCR-13-0275 moter (23), and to accelerate tumor formation in conjunc- Ó2014 American Association for Cancer Research. tion with TP53 deletion (23). 4442 Clin Cancer Res; 20(17) September 1, 2014 Downloaded from clincancerres.aacrjournals.org on September 29, 2021. © 2014 American Association for Cancer Research. Published OnlineFirst June 23, 2014; DOI: 10.1158/1078-0432.CCR-13-0275 ETS Gene Fusions in Cancer Consistent with their role in prostate cancer and Ewing Following upfront androgen deprivation therapy, many sarcoma progression, ETS transcription factors drive down- patients will relapse with castration-resistant prostate stream signaling pathways with a number of functional cancer. The restoration of androgen signaling (35) and consequences. RNAi-mediated disruption of either TMPRSS2–ERG expression (36) in castration-resistant TMPRSS2–ERG or EWS–FLI1 expression inhibits cell pro- disease provides a foundation for the hypothesis that liferation, invasion, metastasis, and xenograft growth of ETS-positive castration-resistant prostate cancer may be prostate cancer or Ewing sarcoma cell line models that preferentially responsive to next-generation antiandrogen harbor the respective fusions (24–26). Accordingly, the therapy, such as abiraterone acetate. Abiraterone blocks transcriptional program driven by overexpression of ETS androgen synthesis by inhibiting the enzyme cytochrome gene fusions is enriched for invasion and metastasis-asso- P450 17 a-hydroxysteroid dehydrogenase (37) and has ciated gene signatures (1, 27, 28). Recently, our group found improved clinical outcomes for patients with castration- that both prostate cancer and Ewing sarcoma ETS gene resistant disease in large phase III clinical trials (38, 39). fusions induce DNA double-strand breaks (25, 26). This Using patient specimens from smaller phase I/II studies of suggests that ETS gene fusions may drive a mutator pheno- metastatic patients treated with abiraterone, Attard and type and cause increased genomic instability in some cells. colleagues found that the presence of the predominant ETS Given the pathogenic roles of ETS fusions in the progres- fusion, the TMPRSS2:ERG rearrangement, in circulating sion of both prostate cancer and Ewing sarcoma, ETS fusion tumor cells (CTC) correlated with prostate-specific antigen products represent intriguing potential therapeutic targets. (PSA) response (40). In this study, 38% of patients with However, transcription factors, such as the ETS family, have ERG fusion–positive CTCs had a >90% decline in PSA level been notoriously difficult to target (29). Potential strategies with abiraterone, compared with 7% of patients with ERG for targeting ETS fusion genes include therapies directed at fusion–negative CTCs (40). In contrast, Danila and collea- the gene promoter, the RNA transcript, the fusion product gues (41) found that TMPRSS2:ERG status in CTCs was not itself, coregulators of the fusion product, other collaborat- associated with response to abiraterone. As with the castra- ing lesions, and downstream targets of the fusion. Although tion-sensitive setting, these discrepancies raise additional each of these strategies holds promise, this review focuses questions, such as whether ETS fusion status in the CTCs on agents available to patients or currently in clinical trials, accurately reflects fusion status in the metastatic lesions. leading to an emphasis on therapies directed at the andro- To address these questions, a multi-institutional random- gen-responsive promoter (in prostate cancer) or against ized phase II clinical trial (clinicaltrials.gov identifier: coregulators of the fusion product. NCT01576172) was initiated by our group at the University of Michigan with the objective of assessing several key questions, including the relationships between ETS fusion – Clinical Translational Advances status and the response to antiandrogen therapy. Speci- Targeting the promoter of ETS fusions fically, this trial, which requires biopsy of metastatic pro- The fact that the predominant ETS fusions in prostate state cancer lesions for enrollment, prospectively stratifies cancer contain an androgen-responsive promoter (1, 24, 30, patients by ETS fusion status in biopsies before random- 31) provides a strong rationale
Load more

Recommended publications
  • Hippo/YAP Signaling Pathway: a Promising Therapeutic Target In
    Hippo/YAP Signaling Pathway: A Promising Therapeutic Target in Bone Paediatric Cancers? Sarah Morice, Geoffroy Danieau, Françoise Rédini, Bénédicte Brounais-Le-Royer, Franck Verrecchia To cite this version: Sarah Morice, Geoffroy Danieau, Françoise Rédini, Bénédicte Brounais-Le-Royer, Franck Verrecchia. Hippo/YAP Signaling Pathway: A Promising Therapeutic Target in Bone Paediatric Cancers?. Can- cers, MDPI, 2020, 12 (3), pp.645. 10.3390/cancers12030645. inserm-03004096 HAL Id: inserm-03004096 https://www.hal.inserm.fr/inserm-03004096 Submitted on 13 Nov 2020 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. cancers Review Hippo/YAP Signaling Pathway: A Promising Therapeutic Target in Bone Paediatric Cancers? Sarah Morice, Geoffroy Danieau, Françoise Rédini, Bénédicte Brounais-Le-Royer and Franck Verrecchia * INSERM, UMR1238, Bone Sarcoma and Remodeling of Calcified Tissues, Nantes University, 44035 Nantes, France; [email protected] (S.M.); geoff[email protected] (G.D.); [email protected] (F.R.); [email protected] (B.B.-L.-R.) * Correspondence: [email protected]; Tel.: +33-244769116 Received: 4 February 2020; Accepted: 7 March 2020; Published: 10 March 2020 Abstract: Osteosarcoma and Ewing sarcoma are the most prevalent bone pediatric tumors.
    [Show full text]
  • FLI1 Gene Fli-1 Proto-Oncogene, ETS Transcription Factor
    FLI1 gene Fli-1 proto-oncogene, ETS transcription factor Normal Function The FLI1 gene provides instructions for making the FLI protein, which controls the activity (transcription) of genes. Transcription is the first step in the process of producing proteins. The FLI protein is part of a group of related proteins, called the Ets family of transcription factors, that control transcription. The FLI protein attaches (binds) to certain regions of DNA and turns on (activates) the transcription of nearby genes. The proteins produced from these genes control many important cellular processes, such as cell growth and division (proliferation), maturation (differentiation), and survival. The FLI protein is found primarily in blood cells and is thought to regulate their development. Health Conditions Related to Genetic Changes Ewing sarcoma Mutations involving the FLI1 gene cause a type of cancerous tumor known as Ewing sarcoma. These tumors develop in bones or soft tissues such as nerves and cartilage. There are several types of Ewing sarcoma, including Ewing sarcoma of bone, extraosseous Ewing sarcoma, peripheral primitive neuroectodermal tumor, and Askin tumor. The mutations that cause these tumors are acquired during a person's lifetime and are present only in the tumor cells. This type of genetic change, called a somatic mutation, is not inherited. The most common mutation that causes Ewing sarcoma is a rearrangement (translocation) of genetic material between chromosome 11 and chromosome 22. This translocation, written as t(11;22), fuses part of the FLI1 gene on chromosome 11 with part of another gene called EWSR1 on chromosome 22, creating an EWSR1/FLI1 fusion gene.
    [Show full text]
  • Accompanies CD8 T Cell Effector Function Global DNA Methylation
    Global DNA Methylation Remodeling Accompanies CD8 T Cell Effector Function Christopher D. Scharer, Benjamin G. Barwick, Benjamin A. Youngblood, Rafi Ahmed and Jeremy M. Boss This information is current as of October 1, 2021. J Immunol 2013; 191:3419-3429; Prepublished online 16 August 2013; doi: 10.4049/jimmunol.1301395 http://www.jimmunol.org/content/191/6/3419 Downloaded from Supplementary http://www.jimmunol.org/content/suppl/2013/08/20/jimmunol.130139 Material 5.DC1 References This article cites 81 articles, 25 of which you can access for free at: http://www.jimmunol.org/content/191/6/3419.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists by guest on October 1, 2021 • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2013 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Global DNA Methylation Remodeling Accompanies CD8 T Cell Effector Function Christopher D. Scharer,* Benjamin G. Barwick,* Benjamin A. Youngblood,*,† Rafi Ahmed,*,† and Jeremy M.
    [Show full text]
  • Supplementary Figure Legends
    1 Supplementary Figure legends 2 Supplementary Figure 1. 3 Experimental workflow. 4 5 Supplementary Figure 2. 6 IRF9 binding to promoters. 7 a) Verification of mIRF9 antibody by site-directed ChIP. IFNβ-stimulated binding of IRF9 to 8 the ISRE sequences of Mx2 was analyzed using BMDMs of WT and Irf9−/− (IRF9-/-) mice. 9 Cells were treated with 250 IU/ml of IFNβ for 1.5h. Data represent mean and SEM values of 10 three independent experiments. P-values were calculated using the paired ratio t-test (*P ≤ 11 0.05; **P ≤ 0.01, ***P ≤ 0.001). 12 b) Browser tracks showing complexes assigned as STAT-IRF9 in IFNγ treated wild type 13 BMDMs. Input, STAT2, IRF9 (scale 0-200). STAT1 (scale 0-150). 14 15 Supplementary Figure 3. 16 Experimental system for BioID. 17 a) Kinetics of STAT1, STAT2 and IRF9 synthesis in Raw 264.7 macrophages and wild type 18 BMDMs treated with 250 IU/ml as indicated. Whole-cell extracts were tested in western blot 19 for STAT1 phosphorylation at Y701 and of STAT2 at Y689 as well as total STAT1, STAT2, 20 IRF9 and GAPDH levels. The blots are representative of three independent experiments. b) 21 Irf9-/- mouse embryonic fibroblasts (MEFs) were transiently transfected with the indicated 22 expression vectors, including constitutively active IRF7-M15. One day after transfection, 23 RNA was isolated and Mx2 expression determined by qPCR. c) Myc-BirA*-IRF9 transgenic 24 Raw 264.7 were treated with increasing amounts of doxycycline (dox) (0,2µg/ml, 0,4µg/ml, 25 0,6µg/ml, 0,8µg/ml, 1mg/ml) and 50µM biotin.
    [Show full text]
  • Genome-Wide Analysis of the Zebrafish ETS Family Identifies Three Genes Required for Hemangioblast Differentiation Or Angiogenesis
    Genome-Wide Analysis of the Zebrafish ETS Family Identifies Three Genes Required for Hemangioblast Differentiation or Angiogenesis Feng Liu, Roger Patient Abstract—ETS domain transcription factors have been linked to hematopoiesis, vasculogenesis, and angiogenesis. However, their biological functions and the mechanisms of action, remain incompletely understood. Here, we have performed a systematic analysis of zebrafish ETS domain genes and identified 31 in the genome. Detailed gene expression profiling revealed that 12 of them are expressed in blood and endothelial precursors during embryonic development. Combined with a phylogenetic tree assay, this suggests that some of the coexpressed genes may have redundant or additive functions in these cells. Loss-of-function analysis of 3 of them, erg, fli1, and etsrp, demonstrated that erg and fli1 act cooperatively and are required for angiogenesis possibly via direct regulation of an endothelial cell junction molecule, VE-cadherin, whereas etsrp is essential for primitive myeloid/endothelial progenitors (hemangio- blasts) in zebrafish. Taken together, these results provide a global view of the ETS genes in the zebrafish genome during embryogenesis and provide new insights on the functions and biology of erg, fli1, and etsrp, which could be applicable to higher vertebrates, including mice and humans. (Circ Res. 2008;103:1147-1154.) Key Words: zebrafish Ⅲ gene duplication Ⅲ ETS transcription factors Ⅲ hemangioblast Ⅲ angiogenesis ebrafish has been recognized as an excellent genetic and during embryonic development and adulthood and have been Zdevelopmental biology model to study hematopoiesis linked with diverse biological processes, from hematopoiesis, and vessel development. Large numbers of genetic mutants vasculogenesis, and angiogenesis to neurogenesis. Many and transgenic lines in both blood and endothelial lineages important blood and endothelial regulators have well- have become available.
    [Show full text]
  • Supplementary Information
    STEAP1 is associated with Ewing tumor invasiveness SUPPLEMENTARY INFORMATION: SUPPLEMENTARY METHODS: Primer sequences for qRT-PCR For EWS/FLI1 detection, the following primers 5’-TAGTTACCCACCCCAAACTGGAT-3’ (sense), 5’-GGGCCGTTGCTCTGTATTCTTAC-3’ (antisense), and probe 5’-FAM- CAGCTACGGGCAGCA-3’ were used. The concentration of primers and probes were 900 and 250 nM, respectively. Inventoried TaqMan Gene Expression Assays (Applied Biosystems) were used for ADIPOR1 (Hs01114951_m1), GAPDH (Hs00185180_m1), USP18 (Hs00276441_m1), TAP1 (Hs00184465_m1), DTX3L (Hs00370540_m1), PSMB9 (Hs00160610_m1), MMP-1 (Hs00899658_m1), STAT1 (Hs01013996_m1) and STEAP1 (Hs00248742_m1). Constructs and retroviral gene transfer The cDNA encoding EWS/FLI1 was described previously (1). A BglII fragment was subcloned in pMSCVneo (Takara Bio Europe/Clontech). For STEAP1-overexpression STEAP1 coding cDNA was cloned into pMSCVneo. For stable STEAP1 silencing, oligonucleotides of the short hairpin corresponding to the siRNAs were cloned into pSIREN-RetroQ (Takara Bio Europe/Clontech). Retroviral constructs were transfected by electroporation into PT67 cells. Viral infection of target cells was carried out in presence of 4 µg/mL polybrene. Infectants were selected in 600 µg/mL G418 (pMSCVneo) or 2 µg/mL puromycin (pSIREN-RetroQ), respectively. Chromatin-immunoprecipitation (ChIP) 2x107 SK-N-MC and RH-30 cells were fixed in 1% formaldehyde for 8 min. Samples were sonicated to an average DNA length of 500-1000 bp. ChIP was performed with 5 µg of anti-FLI1- antibody (C-19; Santa Cruz, Heidelberg, Germany) added to 0.5 mg of precleared chromatin. page 1 of 23 STEAP1 is associated with Ewing tumor invasiveness Quantitative PCR of immunoprecipitated DNA was performed using SybrGreen (Thermo Fisher Scientific, Dreieich, Germany). FLI1 data of the SK-N-MC cells at individual genomic loci were normalized to the control cell line RH-30, and standardized to a non-regulated genomic locus outside of the STEAP1 locus.
    [Show full text]
  • Germline Variants in ETV6 Underlie Reduced Platelet Formation, Platelet Dysfunction and Increased Levels of Circulating CD34+ Progenitors
    Germline variants in ETV6 underlie reduced platelet formation, platelet dysfunction and increased levels of circulating CD34+ progenitors. Marjorie Poggi, Matthias Canault, Marie Favier, Ernest Turro, Paul Saultier, Dorsaf Ghalloussi, Veronique Baccini, Lea Vidal, Anna Mezzapesa, Nadjim Chelghoum, et al. To cite this version: Marjorie Poggi, Matthias Canault, Marie Favier, Ernest Turro, Paul Saultier, et al.. Germline vari- ants in ETV6 underlie reduced platelet formation, platelet dysfunction and increased levels of cir- culating CD34+ progenitors.. Haematologica, Ferrata Storti Foundation, 2017, 102 (2), pp.282-294. 10.3324/haematol.2016.147694. hal-01478347 HAL Id: hal-01478347 https://hal.archives-ouvertes.fr/hal-01478347 Submitted on 22 Apr 2020 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. ARTICLE Platelet Biology & Its Disorders Germline variants in ETV6 underlie reduced Ferrata Storti EUROPEAN Foundation platelet formation, platelet dysfunction and HEMATOLOGY + ASSOCIATION increased levels of circulating CD34 progenitors Marjorie Poggi,1,* Matthias Canault,1,* Marie Favier,1,2,* Ernest Turro,3,4,* Paul Saultier,1 Dorsaf Ghalloussi,1 Veronique Baccini,1 Lea Vidal,1 Anna Mezzapesa,1 Nadjim Chelghoum,5 Badreddine Mohand-Oumoussa,5 Haematologica 2017 Céline Falaise,6 Rémi Favier,7 Willem H.
    [Show full text]
  • The Activation of Human Dermal Microvascular Cells by Poly(I:C)
    The Activation of Human Dermal Microvascular Cells by Poly(I:C), Lipopolysaccharide, Imiquimod, and ODN2395 Is Mediated by the Fli1/FOXO3A This information is current as Pathway of September 24, 2021. Lukasz Stawski, Grace Marden and Maria Trojanowska J Immunol published online 15 November 2017 http://www.jimmunol.org/content/early/2017/11/14/jimmun ol.1601968 Downloaded from Supplementary http://www.jimmunol.org/content/suppl/2017/11/14/jimmunol.160196 Material 8.DCSupplemental http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists by guest on September 24, 2021 • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2017 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Published November 15, 2017, doi:10.4049/jimmunol.1601968 The Journal of Immunology The Activation of Human Dermal Microvascular Cells by Poly(I:C), Lipopolysaccharide, Imiquimod, and ODN2395 Is Mediated by the Fli1/FOXO3A Pathway Lukasz Stawski, Grace Marden, and Maria Trojanowska Endothelial cell (EC) dysfunction has been associated with inflammatory and autoimmune diseases; however, the factors contributing to this dysfunction have not been fully explored.
    [Show full text]
  • Y-Box Binding Protein-1 Regulates Cell Proliferation and Is Associated with Clinical Outcomes of Osteosarcoma
    FULL PAPER British Journal of Cancer (2013) 108, 836–847 | doi: 10.1038/bjc.2012.579 Keywords: osteosarcoma (OS); Y-box binding protein-1 (YB-1); cell proliferation; atelocollagen Y-box binding protein-1 regulates cell proliferation and is associated with clinical outcomes of osteosarcoma Y Fujiwara-Okada1, Y Matsumoto*,1, J Fukushi1, N Setsu1,2, S Matsuura1,2, S Kamura1, T Fujiwara1, K Iida1, M Hatano1, A Nabeshima1, H Yamada3, M Ono4, Y Oda2 and Y Iwamoto1 1Department of Orthopaedic Surgery, Kyushu University, Fukuoka, Japan; 2Department of Anatomic Pathology, Kyushu University, Fukuoka, Japan; 3Department of the Division of Host Defense, Kyushu University, Fukuoka, Japan and 4Department of Pharmaceutical Oncology, Kyushu University, Fukuoka, Japan Background: Prognosis of osteosarcoma (OS) with distant metastasis and local recurrence is still poor. Y-box binding protein-1 (YB-1) is a multifunctional protein that can act as a regulator of transcription and translation and its high expression of YB-1 protein was observed in OS, however, the role of YB-1 in OS remains unclear. Methods: Y-box binding protein-1 expression in OS cells was inhibited by specific small interfering RNAs to YB-1 (si-YB-1). The effects of si-YB-1 in cell proliferation and cell cycle transition in OS cells were analysed in vitro and in vivo. The association of nuclear expression of YB-1 and clinical prognosis was also investigated by immunohistochemistry. Results: Proliferation of OS cell was suppressed by si-YB-1 in vivo and in vitro. The expression of cyclin D1 and cyclin A were also decreased by si-YB-1.
    [Show full text]
  • Novel Mechanisms of Transcriptional Regulation by Leukemia Fusion Proteins
    Novel mechanisms of transcriptional regulation by leukemia fusion proteins A dissertation submitted to the Graduate School of the University of Cincinnati in partial fulfillment of the requirement for the degree of Doctor of Philosophy in the Department of Cancer and Cell Biology of the College of Medicine by Chien-Hung Gow M.S. Columbia University, New York M.D. Our Lady of Fatima University B.S. National Yang Ming University Dissertation Committee: Jinsong Zhang, Ph.D. Robert Brackenbury, Ph.D. Sohaib Khan, Ph.D. (Chair) Peter Stambrook, Ph.D. Song-Tao Liu, Ph.D. ABSTRACT Transcription factors and chromatin structure are master regulators of homeostasis during hematopoiesis. Regulatory genes for each stage of hematopoiesis are activated or silenced in a precise, finely tuned manner. Many leukemia fusion proteins are produced by chromosomal translocations that interrupt important transcription factors and disrupt these regulatory processes. Leukemia fusion proteins E2A-Pbx1 and AML1-ETO involve normal function transcription factor E2A, resulting in two distinct types of leukemia: E2A-Pbx1 t(1;19) acute lymphoblastic leukemia (ALL) and AML1-ETO t(8;21) acute myeloid leukemia (AML). E2A, a member of the E-protein family of transcription factors, is a key regulator in hematopoiesis that recruits coactivators or corepressors in a mutually exclusive fashion to regulate its direct target genes. In t(1;19) ALL, the E2A portion of E2A-Pbx1 mediates a robust transcriptional activation; however, the transcriptional activity of wild-type E2A is silenced by high levels of corepressors, such as the AML1-ETO fusion protein in t(8;21) AML and ETO-2 in hematopoietic cells.
    [Show full text]
  • Brd4-Bound Enhancers Drive Cell-Intrinsic Sex Differences in Glioblastoma
    Brd4-bound enhancers drive cell-intrinsic sex differences in glioblastoma Najla Kfourya,b,1, Zongtai Qic,d,1, Briana C. Pragere,f, Michael N. Wilkinsonc,d, Lauren Broestla,g, Kristopher C. Berretth, Arnav Moudgilc,d,g, Sumithra Sankararamanc,d, Xuhua Chenc,d, Jason Gertzh, Jeremy N. Riche,i, Robi D. Mitrac,d,2,3, and Joshua B. Rubina,j,2,3 aDepartment of Pediatrics, School of Medicine, Washington University in St. Louis, St. Louis, MO 63110; bDepartment of Neurological Surgery, University of California San Diego, La Jolla, CA 92037; cDepartment of Genetics, School of Medicine, Washington University in St. Louis, St. Louis, MO 63110; dCenter for Genome Sciences and Systems Biology, Washington University in St. Louis, St. Louis, MO 63110; eDivision of Regenerative Medicine, Department of Medicine, University of California San Diego, La Jolla, CA 92037; fCleveland Clinic Lerner College of Medicine, Cleveland, OH 44195; gMedical Scientist Training Program, School of Medicine, Washington University in St. Louis, St. Louis, MO 63110; hDepartment of Oncological Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112; iDepartment of Neurosciences, University of California San Diego, La Jolla, CA 92037; and jDepartment of Neuroscience, School of Medicine, Washington University in St. Louis, St. Louis, MO 63110 Edited by Rene Bernards, The Netherlands Cancer Institute, Amsterdam, The Netherlands, and approved December 25, 2020 (received for review August 21, 2020) Sex can be an important determinant of cancer phenotype, and cancer risk and progression, with the ultimate goal of incorporating exploring sex-biased tumor biology holds promise for identifying sex-informed approaches to treatment to improve survival of all novel therapeutic targets and new approaches to cancer treatment.
    [Show full text]
  • The ETV6-NTRK3 Gene Fusion Encodes a Chimeric Protein Tyrosine Kinase That Transforms NIH3T3 Cells
    Oncogene (2000) 19, 906 ± 915 ã 2000 Macmillan Publishers Ltd All rights reserved 0950 ± 9232/00 $15.00 www.nature.com/onc The ETV6-NTRK3 gene fusion encodes a chimeric protein tyrosine kinase that transforms NIH3T3 cells Daniel H Wai1, Stevan R Knezevich1, Trevor Lucas2,3, Burkhard Jansen2,3, Robert J Kay4 and Poul HB Sorensen*,1 1Department of Pathology, 4480 Oak St., British Columbia's Children's Hospital, Vancouver, British Columbia V6H 3V4, Canada; 2Department of Clinical Pharmacology, Section of Experimental Oncology/Molecular Pharmacology, University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria; 3Department of Dermatology, Division of General Dermatology, University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria; 4Department of Medical Genetics, Terry Fox Laboratory, British Columbia Cancer Agency, 600 W. 10th Avenue, Vancouver, British Columbia, V5Z 4E6, Canada The congenital ®brosarcoma t(12;15)(p13;q25) rearran- Introduction gement splices the ETV6 (TEL) gene on chromosome 12p13 in frame with the NTRK3 (TRKC) neurotrophin-3 Congenital ®brosarcoma (CFS) is a cellular, mitotically receptor gene on chromosome 15q25. Resultant ETV6- active neoplasm of the soft tissues primarily aecting NTRK3 fusion transcripts encode the helix ± loop ± helix infants less than 1 year of age. It is a spindle cell (HLH) dimerization domain of ETV6 fused to the sarcoma which may grow to enormous sizes and can protein tyrosine kinase (PTK) domain of NTRK3. We cause considerable morbidity or mortality. Although show here that ETV6-NTRK3 homodimerizes and is CFS has a high propensity for local recurrence, this capable of forming heterodimers with wild-type ETV6.
    [Show full text]